Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

During the Trading Day
26.63 +8.23 / +44.73%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
26.52 -0.11 / -0.41%
Volume: 16.9K
Health Technology
Pharmaceuticals: Other

Company Description

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics. It develops a portfolio of proprietary and patient-targeted monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. The company's antibody technology, Humaneered, treats serious medical conditions with a primary clinical focus on respiratory diseases and cancer. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.

Contact Information

KaloBios Pharmaceuticals, Inc.
442 Littlefield Avenue
South San Francisco California 94080
P:(650) 243-3100
Investor Relations:



Other institutional9.11%
Individual stakeholders69.96%
Mutual fund holders12.87%

Top Executives

Martin ShkreliChairman & Chief Executive Officer
Geoffrey Thomas YarrantonChief Scientific Officer
Harry LamSenior Vice President-Technical Operations
Anne Borgman HageyAssociate Chief Medical Officer
Donald R. JosephSecretary & Chief Legal Officer